Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16068898 | 0.89 | TAAR1 (0.52) | PDE4APDE4BPDE4CPDE4DTAAR1 | |
| SCHEMBL19628279 | 0.89 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DTAAR1 | |
| SCHEMBL14094904 | 0.86 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DTAAR1 | |
| SCHEMBL4061805 | 0.86 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DTAAR1 | |
| SCHEMBL30422333 | 0.85 | TAAR1 (0.61) | PDE4APDE4BPDE4CPDE4DTAAR1 | |
| SCHEMBL12486805 | 0.85 | TAAR1 (0.61) | PDE4APDE4BPDE4CPDE4DTAAR1 | |
| SCHEMBL24252762 | 0.84 | HTR2A (0.47) | PDE4APDE4BPDE4CPDE4DTAAR1 | |
| SCHEMBL19175614 | 0.84 | GAA (0.60) | PDE4APDE4BPDE4CPDE4DTAAR1 | |
| SCHEMBL5104667 | 0.84 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DTAAR1 | |
| SCHEMBL3220881 | 0.84 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287226-B2 | Mild catalytic reduction of C—O bonds and C═O bonds using a recyclable catalyst system | ORGANOFUEL SWEDEN AB (SE) | 2019-05-14 | — | — | US | disclosed |
| US-20170334819-A1 | A MILD CATALYTIC REDUCTION OF C-O BONDS AND C=O BONDS USING A RECYCLABLE CATALYST SYSTEM | ORGANOFUEL SWEDEN AB (SE) | 2017-11-23 | — | — | US | disclosed |
| CN-101906106-A | New heterogeneous ring compound as the HSP90-inhibitor | CONFORMA THERAPEUTICS CORP | 2010-12-08 | — | — | CN | disclosed |
| CN-1882589-B | Novel heterocyclic compounds as HSP 90-inhibitors | CONFORMA THERAPEUTICS CORP | 2010-06-09 | — | — | CN | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| CN-1882589-A | Novel heterocyclic compounds as HSP 90-inhibitors | CONFORMA THERAPEUTICS CORP (US) | 2006-12-20 | — | — | CN | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-4554075-A | PHANEROCHAETE | NORTH CAROLINA STATE UNIVERSITY (US) | 1985-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334819-A1 | A MILD CATALYTIC REDUCTION OF C-O BONDS AND C=O BONDS USING A RECYCLABLE CATALYST SYSTEM | CBR1, ADH1C, AOC2 | PDE4A 4848/4885PDE4B 4817/4885PDE4C 4839/4885 |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | PDE4A 2261/4885PDE4B 2770/4885PDE4C 2723/4885 |
| US-10287226-B2 | Mild catalytic reduction of C—O bonds and C═O bonds using a recyclable catalyst system | CBR1, ADH1C, CBR3 | PDE4A 4841/4885PDE4B 4793/4885PDE4C 4820/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | PDE4A 2261/4885PDE4B 2770/4885PDE4C 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.